Acurx Pharmaceuticals
ACXP
23 hedge funds and large institutions have $4.24M invested in Acurx Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 7 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
222% more capital invested
Capital invested by funds: $1.32M → $4.24M (+$2.92M)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
28% more funds holding
Funds holding: 18 → 23 (+5)
0.07% more ownership
Funds ownership: 0.34% → 0.4% (+0.07%)
65% less call options, than puts
Call options by funds: $284K | Put options by funds: $822K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.08M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$202K |
| 3 |
BlackRock
New York
|
+$170K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$118K |
| 5 |
State Street
Boston,
Massachusetts
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$750K |
| 2 |
Renaissance Technologies
New York
|
-$28K |
| 3 |
Millennium Management
New York
|
-$20.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$19.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$15.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
26
Two Sigma Securities
New York
| – | -$15.2K | -505 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$10.6K | -355 | Closed |
|
|
AIM
28
Anchor Investment Management
Columbia,
South Carolina
| – | -$6.75K | -225 | Closed |
|
29
Group One Trading
Chicago,
Illinois
| – | -$2.26K | -30 | Closed |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$75 | +1 | +50% |
|
ACXP Hedge Fund Activity: Q4 2023 in Review
23 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q4 2023, worth a combined $4.24M — up 222% from $1.32M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ACXP positions and 7 closed out — a net gain of 5 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.08M. The largest seller was Armistice Capital, exiting entirely with an estimated $750K sold.
- 23 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q4 2023, up from 18 in Q3 2023.
- Funds reported $4.24M of Acurx Pharmaceuticals stock for Q4 2023, up 222% quarter-over-quarter.
- 12 funds opened new Acurx Pharmaceuticals positions in Q4 2023 and 7 closed out, a net change of +5 holders.
- The largest Acurx Pharmaceuticals buyer in Q4 2023 was Vanguard Group, an estimated $1.08M added.
- The largest Acurx Pharmaceuticals seller in Q4 2023 was Armistice Capital, an estimated $750K sold.
Based on aggregated 13F filings for Q4 2023.